| According to an exchange filing, Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin’s lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally.
The projected business potential is approximately $1 million in the first year, and supplies are expected to commence before the end of Q2 FY26.
The company stated that it remains committed to expanding access to high-quality medicines across global markets.
Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products.
The company's consolidated net profit surged 42.7% to Rs 11.93 crore on 39.2% rise in revenue from operations to Rs 111.48 crore in Q1 FY26 over Q1 FY25.
The counter slipped 3.37% to Rs 1,033.05 on the BSE.
|